株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のマウスモデル市場 : タイプ別(近交系、ノックアウト、ハイブリッド)、技術別(マイクロインジェクション、ES細胞)、疾患別(腫瘍学、糖尿病)、サービス別(繁殖、冷凍保存、遺伝子検査)、ケア製品別(寝床、餌)分析および予測

Mice Model Market by Type (Inbred, Knockout, Hybrid), Technology (Microinjection, Embryonic stem Cell), Disease (Oncology, Diabetes), Service (Breeding, Quarantine, Genetic testing) & Care Products (Bedding, Feed) - Analysis & Global Forecast to 2020

発行 MarketsandMarkets 商品コード 293088
出版日 ページ情報 英文 249 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
世界のマウスモデル市場 : タイプ別(近交系、ノックアウト、ハイブリッド)、技術別(マイクロインジェクション、ES細胞)、疾患別(腫瘍学、糖尿病)、サービス別(繁殖、冷凍保存、遺伝子検査)、ケア製品別(寝床、餌)分析および予測 Mice Model Market by Type (Inbred, Knockout, Hybrid), Technology (Microinjection, Embryonic stem Cell), Disease (Oncology, Diabetes), Service (Breeding, Quarantine, Genetic testing) & Care Products (Bedding, Feed) - Analysis & Global Forecast to 2020
出版日: 2016年01月22日 ページ情報: 英文 249 Pages
概要

人間とマウスの生体構造、生理学および遺伝的特徴には顕著な類似点があることから、人間の疾患プロセスを解明することができるため、マウスモデルは研究活動において必須なツールとなっています。こうした利点を活用して、科学的発見や個々の遺伝子の働き、様々な疾患のメカニズム、様々な薬物分子の効果と毒性などの理解を深めることができます。マウスモデルはその小ささ、短い世代時間、加速的生涯、低コスト、省スペースというメリットのおかげで最もよく使われ、薬物療法の研究開発を促進する要因となっています。マウスモデルの世界市場は、2015年には10億5,000万米ドルの規模に達し、その後CAGR(年間複合成長率)7.1%で成長して、2020年には14億9,000万米ドルに達することが予測されています。

当レポートでは、世界のマウスモデル市場を取り上げ、市場を大きくマウスモデルの市場とサービスの市場に区分し、タイプ別・技術別・疾患別・サービス別・地域別に市場の現状と見通しについて調査分析するとともに、競合環境、主要企業のプロファイルをまとめるなどした結果をお届けいたします。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 プレミアムインサイト

  • 世界のマウスモデル市場
  • 地域分析:マウスケア製品市場(タイプ別)
  • マウスモデル市場:技術別(実績および予測)

第5章 市場概要

  • イントロダクション
  • 市場区分
  • 市場動態
    • 市場発展促進要因
      • マウスモデルの継続中革新
      • オーダーメイド医療によってオーダーメイドのヒト化マウスモデル需要が促進
      • 補助金および投資という形での継続的支援
      • 製薬会社の活発な研究開発活動
      • ES細胞だけでなく、ノックアウト/突然変異マウスの開発に関する学会の重要性の高まり
    • 市場発展阻害要因
      • ラットモデル利用の増加
      • ゼブラフィッシュモデル開発の進歩
      • 冷凍保存の恩恵の増大
      • 調査における動物の倫理的使用に関する法規制
      • 動物実験の代替法
    • 市場機会
      • ヒト化マウスモデル需要の増加
      • モノクローナル抗体生産の増加
    • 課題
      • マウスモデル改善の必要性

第6章 タイプ別分析

  • イントロダクション
  • 近交系マウス
  • 非近交系マウス
  • 遺伝子組み換え(ノックアウト/ノックイン)マウス
  • ハイブリッド/コンジェニック・マウス
  • 条件付き/外科的修復済みマウス
  • 自然発生突然変異マウス

第7章 技術別分析

  • イントロダクション
  • マイクロインジェクション
  • ES細胞注射
  • 細胞核の転移酵素
  • その他の技術

第8章 サービス別分析

  • イントロダクション
  • 繁殖サービス
  • 冷凍保存サービス
  • 検疫サービス
  • 再導出サービス
  • モデル・インライセンシング・サービス
  • 遺伝子検査サービス
  • その他のサービス

第9章 疾患別分析

  • イントロダクション
  • 腫瘍学マウスモデル
  • 免疫学および炎症研究向けマウスモデル
  • 糖尿病研究向けマウスモデル
  • 心臓血管研究向けマウスモデル
  • 中枢神経系向けマウスモデル
  • 代謝および調整研究向けマウスモデル
  • その他疾患研究向けマウスモデル

第10章 タイプ別分析

  • イントロダクション
  • ケージ
  • 寝床
  • その他

第11章 地域別分析

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他地域

第12章 競合環境

  • 概要
  • 市場シェア分析
  • 競合状況および動向
    • 協業、合意、戦略的提携関係および合弁事業
    • 補助金および基金
    • ライセンシング
    • 新製品発表
    • 事業拡張
    • 特許
    • 買収
    • その他

第13章 企業プロファイル

  • イントロダクション
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • THE JACKSON LABORATORY
  • TACONIC BIOSCIENCES, INC.
  • ENVIGO
  • COVANCE, INC.
  • JANVIER LABS
  • HARBOUR ANTIBODIES BV
  • TRANSGENIC, INC.
  • GENOWAY SA
  • SAGE LABS, INC. (A SUBSIDIARY OF HORIZON DISCOVERY GROUP PLC)
  • INGENIOUS TARGETING LABORATORY

第14章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 2192

Mice models are indispensable tools in research activities with their capability to elucidate human disease processes, due to striking similarities between the anatomy, physiology, and genetics of humans and mice. These advantages promote scientific discovery, understanding of the functions of individual genes, mechanisms of different diseases, and the effectiveness and toxicities of various drug molecules. Mice models are the most popularly used animal models due to their small size, short generation time, accelerated lifespan, low cost, and requirement of less space. These factors help in accelerating the research and development of drug therapies.

Ongoing innovations in mice models, personalized medicine fuelling the demand for personalized humanized mice models, continuous support in the form of investments and grants, and increase in R&D activities of pharmaceutical industries are some of the factors that are expected to drive the growth of the global mice model market in the coming years.

Market players are continuously focusing on innovations in mice models for research on various human diseases. Growing innovations and advances in mice models are providing increased options to researchers to conduct research activities in particular diseases, which is a major factor driving market growth.

On the other hand, factors like advancements in genetic techniques for the development of genetically modified rats have led to the increased usage of rat models, thereby restraining the mice model market to some extent. In addition, advances in zebrafish model development, increased benefits from cryopreservation, regulations & laws for the ethical use of animals, and alternative methods to animal testing are some factors expected to restrain the growth of the market. Moreover, the continuous need for improved mice models is posing as a major challenge for the global mice model market.

In 2015, the inbred mice are estimated to account for the largest share of the global mice model market, by type while genetically engineered mice models are expected to be the fastest-growing market segment, owing to high investments in the development of new and innovative knockout models that also increases the application areas for the models.

In 2015, North America is expected to account for the largest share of the global mice model market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America's large share is attributed to the revised funding plans by NIH to enhance the reproducibility of results, rising demands for monoclonal antibody production, continued and responsible use of animals ensured by animal care organizations, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada.

The major players in the market are focusing on various strategies (agreements, partnerships, joint ventures, collaborations, geographic expansion, new product launches, funds/grants, licensing, patents, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the models and services offered by top players in the mice model market. The report analyzes the mice model market, by type, technology, disease, service, and mice care products.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the mice model market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for mice models & services across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the mice model market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the mice model market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
      • 2.2.1.1. Key data from secondary sources
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key industry insights
      • 2.2.2.2. Key data from primary sources
      • 2.2.2.3. Key insights from primary sources
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. MARKET FORECAST METHODOLOGY
  • 2.5. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.6. ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL MICE MODEL MARKET
  • 4.2. GEOGRAPHIC ANALYSIS: MICE CARE PRODUCTS MARKET, BY TYPE
  • 4.3. MICE MODEL MARKET, BY TECHNOLOGY (2015 VS. 2020)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Ongoing innovations in mice models
        • 5.3.1.1.1. Mice models for immune diseases
        • 5.3.1.1.2. Mice models for cancer
        • 5.3.1.1.3. Mice models for rare diseases
      • 5.3.1.2. Personalized medicine to fuel the demand for personalized humanized mice models
      • 5.3.1.3. Continuous support in the form of grants and investments
      • 5.3.1.4. Increase in R&D activities of pharmaceutical industries
      • 5.3.1.5. Increasing focus of associations on the development of embryonic stem (ES) cells as well as knockout and mutant mice
        • 5.3.1.5.1. International Mouse Phenotyping Consortium (IMPC)
        • 5.3.1.5.2. International Knockout Mouse Consortium (IKMC)
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Increased usage of rat models
      • 5.3.2.2. Advances in zebrafish model development
      • 5.3.2.3. Increased benefits from cryopreservation
      • 5.3.2.4. Regulations and laws for ethical use of animals in research
        • 5.3.2.4.1. The Animal Welfare Act (AWA)
        • 5.3.2.4.2. Public Health Service Policy (PHS)on Humane Care and Use of Laboratory Animals
      • 5.3.2.5. Alternative methods to animal testing
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Rising demand of humanized mice models
      • 5.3.3.2. Increase in monoclonal antibody production
    • 5.3.4. CHALLENGE
      • 5.3.4.1. Need for improved mice models

6. MICE MODEL MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. INBRED MICE
  • 6.3. OUTBRED MICE
  • 6.4. GENETICALLY ENGINEERED (KNOCKOUT & KNOCKIN) MICE
  • 6.5. HYBRID/CONGENIC MICE
  • 6.6. CONDITIONED/SURGICALLY MODIFIED MICE
  • 6.7. SPONTANEOUS MUTANT MICE

7. MICE MODEL MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. MICROINJECTION
  • 7.3. EMBRYONIC STEM CELL INJECTION
  • 7.4. NUCLEAR TRANSFERASE
  • 7.5. OTHER TECHNOLOGIES
    • 7.5.1. GENETICALLY MODIFIED SPERM-MEDIATED GENE TRANSFER
    • 7.5.2. VIRUS/VECTOR-MEDIATED GENE TRANSFER
    • 7.5.3. LIPOSOME-MEDIATED DNA AND ELECTROPORATION OF DNA
    • 7.5.4. BIOLISTICS
    • 7.5.5. CRISPR/CAS9, TALENS, AND ZFNS

8. MICE MODEL MARKET, BY SERVICE

  • 8.1. INTRODUCTION
  • 8.2. BREEDING SERVICES
  • 8.3. CRYOPRESERVATION SERVICES
  • 8.4. QUARANTINE SERVICES
  • 8.5. REDERIVATION SERVICES
  • 8.6. MODEL IN-LICENSING SERVICES
  • 8.7. GENETIC TESTING SERVICES
  • 8.8. OTHER SERVICES

9. MICE MODEL MARKET, BY DISEASE

  • 9.1. INTRODUCTION
  • 9.2. ONCOLOGY MICE MODELS
    • 9.2.1. CONTINUOUS GRANTS/FUNDS TO SUPPORT CANCER RESEARCH STUDIES
    • 9.2.2. AGREEMENTS/COLLABORATIONS TO STRENGTHEN CANCER RESEARCH
    • 9.2.3. INTRODUCTION OF NEW MICE MODELS FOR SPECIFIC CANCERS
    • 9.2.4. EXPANSIONS TO SUPPORT CANCER RESEARCH FACILITIES
  • 9.3. MICE MODELS FOR IMMUNOLOGY AND INFLAMMATION STUDIES
  • 9.4. MICE MODELS FOR DIABETES STUDIES
  • 9.5. MICE MODELS FOR CARDIOVASCULAR STUDIES
  • 9.6. MICE MODELS FOR CENTRAL NERVOUS SYSTEM (CNS) STUDIES
  • 9.7. MICE MODELS FOR METABOLISM AND REGULATION STUDIES
  • 9.8. MICE MODELS FOR OTHER DISEASE STUDIES

10. MICE CARE PRODUCTS MARKET, BY TYPE

  • 10.1. INTRODUCTION
  • 10.2. CAGES
  • 10.3. FEED
  • 10.4. BEDDING
  • 10.5. OTHERS

11. MICE MODEL MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
      • 11.2.1.1. Revised funding plans by the NIH to enhance reproducibility of results
      • 11.2.1.2. Growing biomedical research in the U.S.
      • 11.2.1.3. Monoclonal antibody production to augment the use of mice models
      • 11.2.1.4. Continued and responsible use of animals ensured by Animal Care Organizations
      • 11.2.1.5. Development of biosimilars boosting the demand for preclinical services
      • 11.2.1.6. Preclinical activities by CROs and pharmaceutical R&D
      • 11.2.1.7. Partnerships between CROs and pharmaceutical companies
    • 11.2.2. CANADA
      • 11.2.2.1. Growing stem cell research activities in Canada
  • 11.3. EUROPE
    • 11.3.1. GERMANY
      • 11.3.1.1. Launch of Pro-Test Deutschland
      • 11.3.1.2. Flourishing biotechnology industry
    • 11.3.2. U.K.
      • 11.3.2.1. Investors demand strong statistics for animal studies in the U.K.
      • 11.3.2.2. Increase in cell therapy preclinical research
    • 11.3.3. FRANCE
      • 11.3.3.1. Funding for rare disease projects in France
    • 11.3.4. REST OF EUROPE (ROE)
      • 11.3.4.1. Improving biomedical industry in Russia
      • 11.3.4.2. Growth in biosimilars market calls for increased preclinical activities
      • 11.3.4.3. Focus on rare disease research projects
      • 11.3.4.4. Events conducted by animal care associations to promote the ethical use of mice
      • 11.3.4.5. Increase in tailored mice models for diseases like cancer
  • 11.4. ASIA-PACIFIC
    • 11.4.1. CHINA
      • 11.4.1.1. International alliances for R&D activities in China
      • 11.4.1.2. Growing foray of pharmaceutical and mice model suppliers in China
      • 11.4.1.3. Increasing investments from government and private sectors in China's life sciences sector
      • 11.4.1.4. Initiatives to reduce longer approval times
      • 11.4.1.5. Mandatory animal testing for all pharmaceutical drugs and cosmetics in China
      • 11.4.1.6. Intellectual property (IP) breaches, a challenge for the Chinese market
    • 11.4.2. JAPAN
      • 11.4.2.1. Growth in biomedical and medical research in Japan
      • 11.4.2.2. Research into regenerative medicines
    • 11.4.3. INDIA
      • 11.4.3.1. Growing presence of global players
      • 11.4.3.2. Development of bioclusters to boost India's biotechnology industry
      • 11.4.3.3. R&D activities by Indian pharmaceutical companies to boost preclinical research
      • 11.4.3.4. Likely shift of outsourcing preclinical activities from India towards European nations
      • 11.4.3.5. Limited infrastructural facilities in India, a major hindrance to the mice model market
      • 11.4.3.6. Weak intellectual property environment in India
    • 11.4.4. REST OF ASIA-PACIFIC (ROAPAC)
      • 11.4.4.1. Influx of international players
      • 11.4.4.2. Ongoing biomedical research activities in Australia to strengthen the market
      • 11.4.4.3. Growth in translational and biomedical research in Singapore
      • 11.4.4.4. Increase in animal research in Malaysia
      • 11.4.4.5. Rising pharmaceutical and biotechnology R&D activities in Korea
  • 11.5. REST OF WORLD (ROW)
      • 11.5.1.1. Pharmaceutical, biotechnology, and research industries in Brazil to bolster the market
      • 11.5.1.2. Favorable business environment for pharmaceutical and biotechnology industries in Saudi Arabia and the UAE

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MICE MODEL MARKET: MARKET SHARE ANALYSIS (2014)
    • 12.2.1. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • 12.2.2. THE JACKSON LABORATORY
    • 12.2.3. TACONIC BIOSCIENCES, INC.
    • 12.2.4. HARLAN LABORATORIES, INC. (ENVIGO)
  • 12.3. COMPETITIVE SITUATION AND TRENDS
    • 12.3.1. COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES PARTNERSHIPS, AND JOINT VENTURES
    • 12.3.2. GRANTS & FUNDS
    • 12.3.3. LICENSING
    • 12.3.4. NEW PRODUCT LAUNCHES
    • 12.3.5. EXPANSIONS
    • 12.3.6. PATENTS
    • 12.3.7. ACQUISITIONS
    • 12.3.8. OTHERS

13. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 13.1. INTRODUCTION
  • 13.2. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • 13.3. THE JACKSON LABORATORY
  • 13.4. TACONIC BIOSCIENCES, INC.
  • 13.5. ENVIGO
  • 13.6. COVANCE, INC.
  • 13.7. JANVIER LABS
  • 13.8. HARBOUR ANTIBODIES BV
  • 13.9. TRANSGENIC, INC.
  • 13.10. GENOWAY SA
  • 13.11. SAGE LABS, INC. (A SUBSIDIARY OF HORIZON DISCOVERY GROUP PLC)
  • 13.12. INGENIOUS TARGETING LABORATORY

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. DISCUSSION GUIDE
  • 14.2. COMPANY DEVELOPMENTS (2012-2015)
    • 14.2.1. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • 14.2.2. THE JACKSON LABORATORY (JAX)
    • 14.2.3. TACONIC BIOSCIENCES INC.
    • 14.2.4. ENVIGO
    • 14.2.5. COVANCE, INC.
    • 14.2.6. TRANSGENIC, INC.
    • 14.2.7. GENOWAY SA
    • 14.2.8. SAGE LABS, INC.
  • 14.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.4. AVAILABLE CUSTOMIZATIONS
  • 14.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: ONGOING INNOVATIONS IN MICE MODELS ARE PROPELLING THE GROWTH OF GLOBAL MICE MODEL MARKET
  • TABLE 2: INCREASED USAGE OF RAT MODELS IS LIMITING THE ADOPTION OF MICE MODELS IN RESEARCH
  • TABLE 3: INCREASE IN MONOCLONAL ANTIBODY PRODUCTION USING MICE MODELS HAS A HUGE POTENTIAL FOR THE MICE MODEL MARKET
  • TABLE 4: NEED FOR IMPROVED MICE MODELS IS A MAJOR MARKET CHALLENGE
  • TABLE 5: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 6: INBRED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 7: OUTBRED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 8: GENETICALLY ENGINEERED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 9: HYBRID/CONGENIC MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 10: CONDITIONED/SURGICALLY MODIFIED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 11: SPONTANEOUS MUTANT MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 12: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 13: MICROINJECTION MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 14: EMBRYONIC STEM CELL INJECTION MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 15: NUCLEAR TRANSFERASE MARKET SIZE, BY COUNTRY, 2013-2020 (USD THOUSAND)
  • TABLE 16: OTHER MICE MODEL TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2013-2020 (USD THOUSAND)
  • TABLE 17: GLOBAL MICE MODEL MARKET, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 18: MICE MODEL MARKET SIZE FOR BREEDING SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 19: MICE MODEL MARKET SIZE FOR CRYOPRESERVATION SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 20: MICE MODEL MARKET SIZE FOR QUARANTINE SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 21: MICE MODEL MARKET SIZE FOR REDERIVATION SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 22: MICE MODEL MARKET SIZE FOR MODEL IN-LICENSING SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 23: MICE MODEL MARKET SIZE FOR GENETIC TESTING SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 24: MICE MODEL MARKET SIZE FOR OTHER SERVICES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 25: GLOBAL MICE MODEL MARKET, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 26: RECENT CANCER RESEARCH STUDIES USING MICE MODELS
  • TABLE 27: ONCOLOGY MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 28: MICE MODEL MARKET FOR IMMUNOLOGY AND INFLAMMATION STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 29: MICE MODELS MARKET FOR DIABETES STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 30: MICE MODELS MARKET FOR CARDIOVASCULAR STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 31: RECENT CNS DISORDER-RELATED RESEARCH STUDIES USING MICE MODELS
  • TABLE 32: MICE MODEL MARKET FOR CENTRAL NERVOUS SYSTEM STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 33: MICE MODEL MARKET FOR METABOLISM AND REGULATION STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 34: MICE MODEL MARKET FOR OTHER DISEASE STUDIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 35: GLOBAL MICE CARE PRODUCTS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 36: MICE CARE PRODUCTS MARKET SIZE FOR CAGES, BY REGION, 2013-2020 (USD THOUSAND)
  • TABLE 37: MICE CARE PRODUCTS MARKET SIZE FOR FEED, BY REGION, 2013-2020 (USD THOUSAND)
  • TABLE 38: MICE CARE PRODUCTS MARKET SIZE FOR BEDDING, BY REGION, 2013-2020 (USD THOUSAND)
  • TABLE 39: OTHER MICE CARE PRODUCTS MARKET SIZE, BY REGION, 2013-2020 (USD THOUSAND)
  • TABLE 40: MICE MODEL MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 41: NORTH AMERICA: MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 42: NORTH AMERICA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 43: NORTH AMERICA: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 44: NORTH AMERICA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 45: NORTH AMERICA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 46: NORTH AMERICA: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 47: NIH FUNDING FOR PROJECTS RELATED TO ANIMAL MODELS
  • TABLE 48: ASSOCIATIONS DIRECTLY RELATED TO THE ANIMAL MODEL MARKET
  • TABLE 49: ASSOCIATIONS INDIRECTLY RELATED TO THE ANIMAL MODEL MARKET
  • TABLE 50: U.S.: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 51: U.S.: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 52: U.S.: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 53: U.S.: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 54: CANADA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 55: CANADA: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 56: CANADA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 57: CANADA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 58: EUROPE: MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 59: EUROPE: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 60: EUROPE: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 61: EUROPE: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 62: EUROPE: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 63: EUROPE: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD THOUSAND)
  • TABLE 64: GERMANY: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 65: GERMANY: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 66: GERMANY: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 67: GERMANY: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 68: U.K.: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 69: U.K.: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 70: U.K.: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 71: U.K.: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 72: FRANCE: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 73: FRANCE: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 74: FRANCE: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 75: FRANCE: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 76: STAGES OF PHARMA 2020 STRATEGY
  • TABLE 77: EUROPEAN ANIMAL CARE ASSOCIATIONS AND THEIR EVENTS
  • TABLE 78: ROE: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 79: ROE: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 80: ROE: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 81: ROE: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 82: ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 83: ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 84: ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 85: ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION)
  • TABLE 86: ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 87: ASIA-PACIFIC: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD THOUSAND)
  • TABLE 88: CHINA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 89: CHINA: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 90: CHINA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND)
  • TABLE 91: CHINA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 92: JAPAN: SIGNIFICANT PARTNERSHIPS
  • TABLE 93: JAPAN: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 94: JAPAN: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 95: JAPAN: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND)
  • TABLE 96: JAPAN: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 97: STUDY RESULTS REGARDING R&D EXPENDITURE OF 25 PHARMACEUTICAL COMPANIES
  • TABLE 98: INDIA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 99: INDIA: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 100: INDIA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND)
  • TABLE 101: INDIA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 102: ROAPAC: PLAYER ACTIVITY, 2013 TO 2015
  • TABLE 103: REST OF APAC: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 104: REST OF APAC: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 105: REST OF APAC: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND)
  • TABLE 106: REST OF APAC: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION)
  • TABLE 107: ROW: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD THOUSAND)
  • TABLE 108: ROW: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD THOUSAND)
  • TABLE 109: ROW: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND)
  • TABLE 110: ROW: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD THOUSAND)
  • TABLE 111: ROW: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD THOUSAND)
  • TABLE 112: COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS (2012-2015)
  • TABLE 113: GRANTS & FUNDS, 2012-2015
  • TABLE 114: LICENSING (2012-2015)
  • TABLE 115: NEW PRODUCT LAUNCHES (2012-2015)
  • TABLE 116: KEY PLAYERS FOCUSING ON EXPANSIONS (2012-2015)
  • TABLE 117: PATENTS (2012-2015)
  • TABLE 118: ACQUISITIONS (2012-2015)
  • TABLE 119: KEY PLAYERS FOCUSING ON OTHER STRATEGIES (2012-2015)

LIST OF FIGURES

  • FIGURE 1: GLOBAL MICE MODEL MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: SAMPLING FRAME: PRIMARY RESEARCH
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 6: RESEARCH DESIGN
  • FIGURE 7: DATA TRIANGULATION METHODOLOGY
  • FIGURE 8: NORTH AMERICA DOMINATES THE GLOBAL MICE MODEL MARKET
  • FIGURE 9: CRYOPRESERVATION SERVICES MARKET TO GROW AT THE HIGHEST CAGR FROM 2015 TO 2020
  • FIGURE 10: ASIA-PACIFIC IS EXPECTED TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 11: ONGOING INNOVATIONS IN MICE MODELS TO SPUR MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 12: NORTH AMERICA DOMINATED THE MICE CARE PRODUCTS MARKET IN 2015
  • FIGURE 13: ASIA-PACIFIC MARKET TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 14: MICROINJECTION TECHNOLOGY COMMANDED THE LARGEST SHARE IN 2015
  • FIGURE 15: GLOBAL MICE MODEL MARKET SEGMENTATION
  • FIGURE 16: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: GENETICALLY ENGINEERED MICE TO BE THE FASTEST GROWING SEGMENT
  • FIGURE 18: MICROINJECTION TECHNOLOGY COMMANDED THE LARGEST SHARE OF MICE MODEL MARKET IN 2015
  • FIGURE 19: MICE MODEL MARKET, BY SERVICE
  • FIGURE 20: BREEDING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE MICE MODEL MARKET IN 2015
  • FIGURE 21: MICE MODEL MARKET, BY DISEASE
  • FIGURE 22: ONCOLOGY MICE MODELS TO DOMINATE THE MICE MODEL MARKET IN 2015
  • FIGURE 23: MICE CARE PRODUCTS MARKET, BY TYPE
  • FIGURE 24: CAGES ACCOUNTED FOR THE LARGEST SHARE OF THE MICE CARE PRODUCTS MARKET IN 2015
  • FIGURE 25: ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR IN THE MICE MODEL MARKET DURING THE FORECAST PERIOD
  • FIGURE 26: THE U.S. COMMANDED THE LARGEST SHARE IN THE MICE MODEL MARKET IN NORTH AMERICA IN 2015
  • FIGURE 27: GERMANY DOMINATED THE EUROPEAN MICE MODEL MARKET IN 2015
  • FIGURE 28: NUMBER OF CELL THERAPY PRECLINICAL STUDIES LISTED IN THE PRECLINICAL RESEARCH DATABASE IN THE U.K., 2013-2015
  • FIGURE 29: CHINA: THE FASTEST GROWING COUNTRY IN THE ASIA-PACIFIC MICE MODEL MARKET
  • FIGURE 30: CHINA PHARMA PARTNERING ACTIVITY BY STAGE - 2009-2014
  • FIGURE 31: ONCOLOGY MICE MODELS TO DOMINATE THE ROW MICE MODELS MARKET, BY DISEASES
  • FIGURE 32: MAJOR PLAYERS FOCUSED ON INORGANIC GROWTH STRATEGIES
  • FIGURE 33: MICE MODEL MARKET SHARE, BY KEY PLAYER, 2014
  • FIGURE 34: BATTLE FOR MARKET SHARE: MAJOR COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS FORMED THE KEY STRATEGY (2012-2015)
  • FIGURE 35: KEY PLAYERS FOCUSING ON COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS (2012-2015)
  • FIGURE 36: KEY PLAYERS FOCUSING ON GRANTS & FUNDS (2012-2015)
  • FIGURE 37: KEY PLAYERS FOCUSING ON LICENSING (2012-2015)
  • FIGURE 38: KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCHES (2012-2015)
  • FIGURE 39: KEY PLAYERS FOCUSING ON EXPANSIONS (2012-2015)
  • FIGURE 40: KEY PLAYERS FOCUSING ON PATENTS (2012-2015)
  • FIGURE 41: KEY PLAYERS FOCUSING ON ACQUISITIONS (2012-2015)
  • FIGURE 42: KEY PLAYERS FOCUSING ON OTHER STRATEGIES (2012-2015)
  • FIGURE 43: BUSINESS FOCUS OF TOP MARKET PLAYERS
  • FIGURE 44: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
  • FIGURE 45: THE JACKSON LABORATORY: COMPANY SNAPSHOT
  • FIGURE 46: COVANCE, INC.: COMPANY SNAPSHOT
  • FIGURE 47: GENOWAY SA: COMPANY SNAPSHOT
Back to Top